NCT07831369RecruitingPhase 2
VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in patients with recurrent glioblastoma and adults with recurrent IDH-mutated gliomas
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- First submitted
- 9 Sept 2026
- Start date
- 4 Sept 2026
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Inova Health Care Services
- Diseases
- Glioblastoma
- NCT number
- NCT07831369
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 52
- From 4 Sept 2026 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with irinotecan
- Prior use of valproic acid within 2 months
Other illness
- Active bacterial or fungal infection requiring systemic treatment
- Known mitochondrial disease
Other
- Use of an enzyme-inducing antiepileptic or other strong inducer of CYP3A4
- Anticancer treatment within 4 weeks, 6 weeks if nitrosourea
- Pregnancy
Who the study is looking for
- Diagnosis of glioblastoma or IDH-mutated glioma by WHO 2021 classification
- For glioblastoma, at least one prior treatment, which needs to include temozolomide and/or radiation
- For IDH-mutated glioma, prior treatment with both radiation and alkylating chemotherapy
- Evidence of progression by RANO 2.0 criteria on MRI within last four weeks
- At least 1 enhancing measurable lesion
Age in the registry: 18 years to 98 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Inova Schar Cancer Coordinator of this site? Confirm its status | Fairfax | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.